New Therapies for Anemia Management in CKD
An Interactive Symposium on the Full Spectrum of Kidney Disease


World Congress of Nephrology (ASN/ISN), San Francisco, October, 2001
Before listening to the TALK,take the same quiz that was given to the San Francisco audience and compare your results with theirs.
A global look at chronic kidney disease (CKD): The quest to improve patient outcomes
Brian J.G. Pereira, M.D.
Health care economics: The impact of anemia management
Allan J. Collins, M.D.
Anemia in chronic kidney disease: The heart of the matter
Adeera Levin, M.D.
Darbepoetin alfa (Aranesp™): A further step in anemia treatment
Francesco Locatelli, M.D.
Questions and answers 
Access to this program is free but HDCN free zone registration is required.
Upon completion of this activity, participants should be able to:
  • Discuss the prevalence of chronic kidney disease (CKD) and anemia of CKD
  • Discuss the problem of underdiagnosis and undertreatment of anemia
  • Explain the relationship between effective management of chronic kidney disease and clinical outcomes
  • Describe new data related to pre-dialysis patients
  • Identify the economic impact of anemia management
  • Describe the link between CKD, anemia, and heart disease
Allan Collins, M.D.
Minneapolis Medical Research Foundation
Minneapolis, Minnesota

Adeera Levin, M.D.
Associate Clinical Professor
Director, Postgrad Education, Nephrology
University of British Columbia
St. Paul's Hospital
Vancouver, British Columbia

Francesco Locatelli, M.D.

Scientific Director and Chief of Nephrology Department,
A. Manzoni Hospital
Lecco, Italy

Brian J. G. Pereira, M.D., M.B.A.
Senior Vice-President
New England Medical Center
Louisa C. Endicott Professor of Medicine
Tufts Univ. School of Medicine Boston, Massachusetts.
The Postgraduate Institute for Medicine designates this activity for a maximum of 2 hours in category 1 credit toward the AMA Physician's Recognition Award.
Estimated time to complete activity: 2.0 hours
Posting date: December 15, 2001
Review date: December 15, 2002
Expiration date: December 15, 2003 #

To obtain a statement of participation, you must complete the post-test by recording the best answer to each question in the answer key on the evaluation form, complete the evaluation form, and mail or fax the evaluation form with answer key to the Postgraduate Institute for Medicine.

Post-test and evaluation form is at this link, but you must listen to all four talks from this symposium prior to completing the test

TARGET AUDIENCE :
This activity has been designed to meet the educational needs of nephrologists involved in the treatment of patients with CKD and anemia.

STATEMENT OF NEED :
Chronic kidney disease affects 30-40 million Americans and is hence a major health care problem. Anemia of CKD is a preventable and treatable complication of CKD and is yet under recognized and under treated. Nephrologists should be sensitized to the above two facts and are the target audience for this message. This emerging information would be necessary to improve anemia management and consequently classical outcomes.

ACCREDITATION STATEMENT :
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and HealthVizion Communications. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality, and scientific integrity of this CME activity.

DESIGNATION STATEMENT(S) :
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 2 hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

FACULTY DISCLOSURE STATEMENTS :
Postgraduate Institute for Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Dr. Collins: Grants/Research Support: Amgen, Inc.
Dr. Levin: Grants/Research Support and Consultant: Amgen, Inc., Genzyme Inc., Ortho Biotech, Roche Pharmaceuticals, Jansen
Dr. Locatelli: Dr. Locatelli had no financial relationships with commercial entities related to his presentation
Dr. Pereira: Grants/Research Support: Amgen, Inc.
Consultant: Amgen, Inc., Baxter;   Speakers' Bureau: Amgen, Inc.

DISCLOSURE OF UNLABELED USE :
Faculty of this CME activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members will disclose to the audience any reference to an unlabeled or investigational use. The Postgraduate Institute for Medicine, HealthVizion Communications, and Amgen, Inc. do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

DISCLAIMER :
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


This educational activity jointly sponsored by Postgraduate Institute for Medicine and Healthvizion Communications.
This educational activity is supported by an educational grant from Amgen, Inc.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies